TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34694223
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FC; 1,000 mg, single dose)
Study: 34694223
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (IS; 200 mg every 48 hours until covering the total iron deficit or discharge)
Study: 32053119
Drug: SMS text
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS text messaging intervention (CARE+ Corrections), participants received weekly or daily SMS text messages for 6 months.
Study: 33538999
Drug: Patients' Own
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' Own Medicines (POMs)
Study: 32213517
Drug: 12-week group
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week group cognitive-behavioural therapy (CBT) programme
Study: 32812129
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser combined with intralesional steroid (Triamcinolone acetonide)
Study: 35170392
Drug: Salinomycin (69
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salinomycin (69 mg/kg feed)
Study: 35170392
Drug: Encapsulated Butyrate
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated Butyrate (EB) (500 mg/kg)
Study: 35170392
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no dietary supplement)
Study: 32450901
Drug: Training programme
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training programme (5-day training including evidence-based medicine training module and application of the guideline)
Study: 37523429
Drug: Repeated low-level
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated low-level red-light (RLRL) therapy
Study: 37099298
Drug: RLRL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLRL therapy
Study: 35922823
Drug: Endoscopic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic intervention (endoscopic bulking injections)
Study: 33500258
Drug: PD-1 inhibitors
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitors (treatment duration: median 11.1 months)
Study: 32083290
Drug: Adjuvant S1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant S1 therapy
Study: 32083290
Drug: Modified FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFIRINOX regimen as adjuvant therapy
Study: 33591032
Drug: ADASCs alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADASCs alone (3 × 10⁶ cells/1 mL) in Group 1 (n = 5)
Study: 33591032
Drug: 120-μm lamina
Normalized name: CROSPOVIDONE (120 .MU.M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120-μm lamina recellularized with ADASCs (1 × 10⁶ cells/1 mL) in Group 3 (n = 4)
Study: 34271931
Drug: Perceptions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceptions of diarrhoea treatment
Study: 35462408
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment based on patient goals and values
Study: 34591549
Drug: panic control
Normalized name: BENZALKONIUM CHLORIDE 1 g in 59 mL TOPICAL GEL [Donut Panic Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: panic control treatment (PCT)
Study: 37574610
Drug: LEM5 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEM5 (5 mg)
Study: 37574610
Drug: LEM10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEM10 (10 mg)
Study: 35770861
Drug: Multinutrient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multinutrient treatment
Study: 35123779
Drug: 1‐flunixin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐flunixin group (1‐FLU, n = 26) with a single administration of transdermal flunixin meglumine at disbudding
Study: 35123779
Drug: 2‐flunin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐flunin group (2‐FLU, n = 24) with 2 administrations of transdermal flunixin meglumine, the first treatment at disbudding and the second 6 h after disbudding
Study: 34675472
Drug: Oxymetazoline 0.1%
Normalized name: OXYMETAZOLINE 0.1% (PF) SOLN,OPH,UD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline 0.1% ophthalmic solution, administered once daily for 14–84 days
Study: 34675472
Drug: Placebo (vehicle),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle), administered once daily for 14–84 days
Study: 34675472
Drug: Oxymetazoline 0.1%
Normalized name: OXYMETAZOLINE 0.1% (PF) SOLN,OPH,UD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline 0.1% ophthalmic solution
Study: 32599131
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel applied to abdominal area (treatment group A)
Study: 32599131
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel applied to upper arms/shoulders (treatment group B)
Study: 35774276
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of sweet almond oil (126 ml over 7 sessions in 2 weeks, 18 ml every other day)
Study: 35774276
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage with sweet almond oil (same amount as oral group, during 7 sessions in 2 weeks)
Study: 35774276
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of sweet almond oil
Study: 33974129
Drug: 150 µg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 µg/d iodine
Study: 33974129
Drug: 300 µg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 µg/d iodine
Study: 34034960
Drug: Gradual adaptation
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual adaptation (4 h on the first day, increasing by 2 h daily until 10 h)
Study: 35002557
Drug: Inhaled Budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Budesonide (BUD) 2 mL, 0.25‐mg/mL suspension, inhalation, twice daily for 5 days
Study: 35002557
Drug: Placebo (humidified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (humidified distilled sterile water inhalation, 2 mL)
Study: 34452681
Drug: Behavioral Therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Therapy Team (BTT) intervention consisting of individual information-gathering sessions followed by 12 weeks of group ERP and concurrent home-based coaching sessions
Study: 34452681
Drug: Behavioral Therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Therapy Team (BTT) intervention
Study: 32372186
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri LR92 DSM 26866 (1 × 10^8 CFU daily for 4 weeks)
Study: 32372186
Drug: Placebo (9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (9% glucose solution for 4 weeks)
Study: 33763126
Drug: Neurological music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurological music therapy
Study: 36063826
Drug: EV 4
Normalized name: Zirabev 400 MG in 16 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV 4 mg/d
Study: 36063826
Drug: EV 6
Normalized name: Emeprev 60 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV 6 mg/d
Study: 36063826
Drug: EV 9
Normalized name: Summer's Eve Medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV 9 mg/d
Study: 35635201
Drug: Daily application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of negatively charged polystyrene microspheres (NCMs)
Study: 32171252
Drug: Network-offered training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Network-offered training programs focusing on best practice guideline-oriented use of antibiotics
Study: 35941669
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin once daily for 28 days
Study: 32895226
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 1.5 mg bolus given every 10 min until NRS pain score <4
Study: 32895226
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus morphine 0.05 mg/kg body weight followed by 0.025 mg/kg/hour intravenous infusion
Study: 33400384
Drug: Reminiscence therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy-based care program (RTCP)
Study: 32617881
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG injection 36 hours before oocyte retrieval
Study: 32617881
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) injection 36 hours before oocyte retrieval
Study: 32617881
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection 36 hours before oocyte retrieval
Study: 33020080
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HLS-EU-Q16 and NVS measures.
Study: 34063322
Drug: Taurisolo� (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurisolo� (20 mg/Kg/die)
Study: 34063322
Drug: Taurisolo� (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurisolo� (400 mg twice daily for 8 weeks)
Study: 35587723
Drug: 0.1% HA2k
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% HA2k lotion
Study: 35587723
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control lotion
Study: 35587723
Drug: 0.1% HA2k
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% HA2k solution
Study: 33934058
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (docetaxel, oxaliplatin, capecitabine; Arm A)
Study: 33934058
Drug: No induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No induction chemotherapy (Arm B)
Study: 33934058
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (Arm A)
Study: 34016350
Drug: N-acetyl-l-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl-l-cysteine (NAC) 1000 mg/kg in basal diet
Study: 34397100
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate
Study: 32048384
Drug: Personal consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal consumption of hypnotic drugs
Study: 32048384
Drug: Personal consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal consumption of anxiolytics
Study: 32048384
Drug: Personal drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal drug consumption
Study: 34432008
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens alone or combined with estrogen-progestin therapy
Study: 34432008
Drug: Transdermal routes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal routes of HT administration
Study: 34432008
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with natural progesterone
Study: 34432008
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of HT
Study: 32055041
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg intravenous)
Study: 33589311
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group 2) - advised to take a liquid diet of their own choice, including shakes, juices, and milk, along with protein supplements.
Study: 32102557
Drug: Intensity-modulated radiotherapy
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated radiotherapy (IMRT) using pre-induction chemotherapy (IC) images (Group A)
Study: 32102557
Drug: Intensity-modulated radiotherapy
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated radiotherapy (IMRT) using post-induction chemotherapy (IC) images (Group B)
Study: 36410799
Drug: Active transdermal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transdermal glyceryl trinitrate
Study: 35929990
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C (1.5 g/kg/d, intravenously for 3 hours from D1 to D3) plus FOLFOX +/- bevacizumab
Study: 35929990
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C plus FOLFOX +/- bevacizumab
Study: 33825412
Drug: Integrated Traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Traditional Chinese and Western Medicine (IM)
Study: 33398361
Drug: Nonvitamin K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonvitamin K oral anticoagulants (NOACs)
Study: 34043064
Drug: Diphenhydramine 0.5
Normalized name: DIPHENHYDRAMINE 0.5%/HC 0.5% SPRAY,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 0.5 mg/kg before anesthesia induction
Study: 34097062
Drug: EQW/DAPA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: EQW/DAPA (2 mg weekly/10 mg daily)
Study: 34097062
Drug: PHEN/TPM (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHEN/TPM (7.5 mg/46 mg ER daily)
Study: 34097062
Drug: EQW (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: EQW (2 mg weekly)
Study: 34097062
Drug: DAPA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPA (10 mg daily)
Study: 34097062
Drug: DAPA/MET (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPA/MET (10 mg/2000 mg XR daily)
Study: 33497408
Drug: Pain treatment
Normalized name: ARNICA MONTANA FLOWER 10 g in 50 g / SALIX ALBA BARK 15 g in 50 g / FRANKINCENSE 10 g in 50 g TOPICAL CREAM [HOUKEA Bone Pain Treatment Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain treatment groups
Study: 32650683
Drug: ATG (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG (4.5 mg/kg thymoglobulin plus cyclosporine [CsA], methotrexate [MTX], and mycophenolate mofetil [MMF])
Study: 35139937
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no platelet-rich plasma gel)
Study: 33030582
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation (250 mg/day)
Study: 32293362
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy (CROSS regimen): paclitaxel 50 mg/m2; carboplatin (AUC = 2), q1w, 5 cycles; concurrent radiotherapy, 41.4 Gy/23 F, over 5 weeks
Study: 32293362
Drug: Neoadjuvant chemotherapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy: paclitaxel 175 mg/m2; cisplatin 75 mg/m2, q21d, 2 cycles
Study: 35343294
Drug: Patient adherence
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient adherence to medication and care
Study: 32520820
Drug: Guided internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-delivered pain management treatment
Study: 33772757
Drug: One year
Normalized name: Annovera 0.15 MG / 0.013 MG per 24HR One Year Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: One year of antiseizure medication (ASM) therapy
Study: 33772757
Drug: Three years
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three years of antiseizure medication (ASM) therapy
Study: 33772757
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of initial ASM treatment
Study: 32544121
Drug: Modeled-WALANT state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modeled-WALANT state (after 10 mL of 1% lidocaine injection)
Study: 35352668
Drug: Peri-urethral injection
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-urethral injection of autologous mucosa stem cells
Study: 33637835
Drug: Second-generation antipsychotic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotic (risperidone or paliperidone)
Study: 35081130
Drug: Blended Acceptance
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended Acceptance and Commitment Therapy (ACT)
Study: 33769293
Drug: Face-to-face Cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face Cognitive Behavioral Therapy (CBT)
Study: 34742136
Drug: n3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n3 PUFA (930 mg EPA + 660 mg DHA)
Study: 32089006
Drug: Alirocumab (75-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75-150 mg every 2 weeks)
Study: 35239547
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg single-dose oral cannabidiol
Study: 32653074
Drug: Medium-dose MF–IND–GLY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose MF–IND–GLY (80 μg, 150 μg, 50 μg)
Study: 32653074
Drug: High-dose MF–IND–GLY
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MF–IND–GLY (160 μg, 150 μg, 50 μg)
Study: 35848622
Drug: Minocycline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline treatment
Study: 32662833
Drug: Yoga or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga or Physical Therapy (PT)
Study: 32662833
Drug: Yoga or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga or PT (with pain medication)
Study: 32662833
Drug: Yoga or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga or PT (without pain medication)
Study: 32800383
Drug: Surufatinib 250
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib 250 mg capsules in the fasted state
Study: 32800383
Drug: Surufatinib 250
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib 250 mg capsules in the fed state
Study: 32800383
Drug: Surufatinib 250
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib 250 mg capsules (both fasted and fed states)
Study: 35633431
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment for one year in men aged ≥ 65 years
Study: 35633431
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment for two years in men aged 50–74 years
Study: 34117564
Drug: 35% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% hydrogen peroxide gel (35% HP, commercial gel)
Study: 34117564
Drug: 35% HP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% HP and calcium (35% HP + Ca, commercial gel)
Study: 34013852
Drug: Individual Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Cognitive Behavioural Therapy (ICBT)
Study: 34013852
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavioural Therapy (GCBT)
Study: 34106473
Drug: Short 3-item
Normalized name: short ragweed pollen extracts
DrugBank: Ambrosia artemisiifolia pollen (DB10385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short 3-item version of the Montreal Cognitive Assessment (MoCA) administered by telephone
Study: 32213163
Drug: Neostigmine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (50 mcg/kg plus 10 mcg/kg of atropine)
Study: 35833308
Drug: Conventional wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional wound treatment
Study: 35452417
Drug: Wnt/β‐catenin pathway
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wnt/β‐catenin pathway inhibitors
Study: 35585593
Drug: Shared meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shared meditation intervention (12 weekly sessions of 1.5 hours and a half-day retreat)
Study: 32644104
Drug: Fluorouracil-based adjuvant
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil-based adjuvant chemotherapy with oxaliplatin
Study: 34528723
Drug: Pemafibrate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate 0.2 mg, orally, twice daily for 72 weeks
Study: 33413727
Drug: 7.5 g
Normalized name: glucose 15 GM per 37.5 GM Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g of salmon fish protein/d
Study: 35712916
Drug: Guided Self-Help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided Self-Help (GSH) program, 14 individual sessions over 6 months, 5.3 hours of treatment
Study: 35712916
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral treatment (FBT), 20 group-based sessions over 6 months, 20 hours of treatment
Study: 33401238
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg·kg‐1 of body mass)
Study: 34387126
Drug: Cardiac neuromodulation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac neuromodulation therapy (CNT)
Study: 36038256
Drug: 5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg/day caffeine citrate